Wang L, Luo Y, Ren S, Zhang Z, et al. A phase Ib study of ivonescimab, a PD-1/VEGF bispecific antibody, as first- or second-line therapy for advanced or metastatic immunotherapy naive non-small-cell lung cancer. J Thorac Oncol 2023 Oct 23:S1556-0864(23)02312.
PMID: 37879536